NCT01392183 2021-09-20Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)M.D. Anderson Cancer CenterPhase 2 Completed69 enrolled 15 charts
NCT00782275 2018-01-24Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell CarcinomaDana-Farber Cancer InstitutePhase 2 Completed41 enrolled 9 charts